Cargando…

Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature

Metastatic pheochromocytoma and paraganglioma (PPGL) are rare diseases with dismal prognosis and standard therapies are lacking. We herein report the first case of a germline anaplastic lymphoma kinase (ALK) mutation in a patient with chemorefractory metastatic pheochromocytoma in the absence of mut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heregger, R., Huemer, F., Hutarew, G., Hecht, S., Cheveresan, L., Kotzot, D., Schamschula, E., Rinnerthaler, G., Melchardt, T., Weiss, L., Greil, R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358412/ https://www.ncbi.nlm.nih.gov/pubmed/34371380 http://dx.doi.org/10.1016/j.esmoop.2021.100233

Ejemplares similares

Postoperative chemoradiotherapy with cisplatin is superior to radioimmunotherapy with cetuximab and radiotherapy alone: Analysis of the Austrian head and neck cancer registry of the AGMT
por: Magnes, Teresa, et al.
Publicado: (2021)

Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol
por: Huemer, Florian, et al.
Publicado: (2022)

Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence
por: Huemer, Florian, et al.
Publicado: (2020)

Impact of antibiotic treatment on immune-checkpoint blockade efficacy in advanced non-squamous non-small cell lung cancer
por: Huemer, Florian, et al.
Publicado: (2018)

Clinical Pharmacology of Brigatinib: A Next-Generation Anaplastic Lymphoma Kinase Inhibitor
por: Gupta, Neeraj, et al.
Publicado: (2023)

Baseline Absolute Lymphocyte Count and ECOG Performance Score Are Associated with Survival in Advanced Non-Small Cell Lung Cancer Undergoing PD-1/PD-L1 Blockade
por: Huemer, Florian, et al.
Publicado: (2019)

Management of metastatic colorectal cancer in patients ≥70 years - a single center experience
por: Huemer, Florian, et al.
Publicado: (2023)

Unraveling Resistance to Immunotherapy in MSI-High Colorectal Cancer
por: Heregger, Ronald, et al.
Publicado: (2023)

Therapy Line and Associated Predictors of Response to PD-1/PD-L1-Inhibitor Monotherapy in Advanced Non-small-Cell Lung Cancer: A Retrospective Bi-centric Cohort Study
por: Lang, David, et al.
Publicado: (2019)

Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice
por: Siaw, Joachim T., et al.
Publicado: (2016)

The Effect of a High‐Fat Meal on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
por: Tugnait, Meera, et al.
Publicado: (2018)

Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence
por: Magnes, T., et al.
Publicado: (2021)

Current Insights on the Treatment of Anaplastic Lymphoma Kinase-Positive Metastatic Non-Small Cell Lung Cancer: Focus on Brigatinib
por: Rijavec, Erika, et al.
Publicado: (2022)

Pharmacometric analyses and clinical evidence for brigatinib dosing in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
por: Gupta, Neeraj, et al.
Publicado: (2022)

P1166: BRIGATINIB IN PATIENTS WITH ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA WHO HAVE FAILED BRENTUXIMAB VEDOTIN
por: Veleanu, Layla, et al.
Publicado: (2023)

Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics
por: Huemer, F, et al.
Publicado: (2019)

Prognostic and Predictive Factors in Advanced Head and Neck Squamous Cell Carcinoma
por: Magnes, Teresa, et al.
Publicado: (2021)

MJRA1.19.2 - Integrated EMI Major Release Candidates
por: Members of EMI collaboration
Publicado: (Febr)

Correction to Lancet Glob Health 2017; 5: e1192–207
Publicado: (2017)

1192. Validation of an Electronic Dashboard in Identifying Excess Duration of Antibiotics for Pneumonia
por: Ferranti, Mary, et al.
Publicado: (2023)

Brigatinib for non-small cell lung cancer
Publicado: (2020)

Investigation into the Formation of Impurities during the Optimization of Brigatinib
por: Guo, Aofeng, et al.
Publicado: (2020)

Effect of severe renal impairment on the pharmacokinetics of brigatinib
por: Gupta, Neeraj, et al.
Publicado: (2021)

Brigatinib pharmacokinetics in patients with chronic hepatic impairment
por: Hanley, Michael J., et al.
Publicado: (2023)

Primary Resistance to Brigatinib in a Patient with Lung Adenocarcinoma Harboring ALK G1202R Mutation and LIPI-NTRK1 Rearrangement
por: Xiao, Zhiwei, et al.
Publicado: (2020)

Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study
por: Gupta, Neeraj, et al.
Publicado: (2020)

P1192: ASIA SUBPOPULATION ANALYSIS FROM THE PHASE III POLARIX TRIAL
por: Song, Y., et al.
Publicado: (2022)

Corrigendum to: Brigatinib dose rationale in anaplastic lymphoma kinase–positive non‐small cell lung cancer: Exposure–response analyses of pivotal ALTA study
Publicado: (2021)

Cost-effectiveness of ensartinib, crizotinib, ceritinib, alectinib, brigatinib and lorlatinib in patients with anaplastic lymphoma kinase-positive non-small cell lung cancer in China
por: Luo, Xia, et al.
Publicado: (2022)

Low Expression of miR-20a-5p Predicts Benefit to Bevacizumab in Metastatic Breast Cancer Patients Treated within the TANIA Phase III Trial
por: Rinnerthaler, Gabriel, et al.
Publicado: (2020)

Spatial Heterogeneity in Large Resected Diffuse Large B-Cell Lymphoma Bulks Analysed by Massively Parallel Sequencing of Multiple Synchronous Biopsies
por: Magnes, Teresa, et al.
Publicado: (2021)

Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer
por: Gupta, Neeraj, et al.
Publicado: (2020)

Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies
por: Li, Bo, et al.
Publicado: (2019)

Synthesis and Preclinical Evaluation of [Methylpiperazine-(11)C]brigatinib as a PET Tracer Targeting Both Mutated Epidermal Growth Factor Receptor and Anaplastic Lymphoma Kinase
por: Högnäsbacka, Antonia A., et al.
Publicado: (2023)

Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort
por: Schlintl, Verena, et al.
Publicado: (2022)

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab
por: Magnes, T., et al.
Publicado: (2019)

Secular trends in 1,192 diarrheal outbreaks in the Israel Defence Forces between 1988–2011
por: Elazar, Sharon, et al.
Publicado: (2015)

1192. H-NS-like Proteins in Pseudomonas aeruginosa Coordinately Silence Intragenic and Antisense Transcription
por: Lippa, Andrew M, et al.
Publicado: (2020)

EP1192: LIVER TEST ABNORMALITIES IN COVID-19 PATIENTS MAY NOT BE RELATED TO CYTOKINE STORM
por: Piskorz, Maria, et al.
Publicado: (2022)

CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer
por: Melchardt, Thomas, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_k8a8c4p2hbict72ju4jmof84al